Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib versus placebo with trastuzumab + pertuzumab maintenance after induction therapy in advanced HER2-positive breast cancer
NL-OMON60823Phase 3Active, not recruiting
- Sponsor
- Seagen Inc.
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Tucatinib + trastuzumab + pertuzumab with Placebo + trastuzumab + pertuzumab (2 arms). Primary endpoint: Progression-free survival by investigator assessment. Started Jun 2023; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60823.